PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis - 2016

  • ID: 3615075
  • Report
  • Region: Global
  • 224 Pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
The report "PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis - 2016" gives an insight on the PD-1 and PD-L1 inhibitors, which are amongst the highly growing fields in biopharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. There are 45 drugs in pipeline with approximate 245 active clinical studies.

The report provides an update on the recent collaborations occurring in the PD-1 and PDL-1 market and the companies looking for partnership for the same. Report also covers Commercial Aspects such as the Current and Future Market, Barriers and challenges and SWOT analysis. Future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. It analyses PD-1 and PD-L1 industry and discusses the key market trends, major players, Key technologies.

Scope

- Overview of PD-1 and PD-L1 inhibitors, role, significance, pathway, mechanism of action (MoA) and biomarkers of PD-1 and PD-L1 inhibitors
- The new report has covered the worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules including along with patent expiry and impact on market after expiry and detail profiling of Pipeline assets
- It also includes Indication wise detailed epidemiology along with trends in epidemiology, incidence and prevalence segmented in to major geographies
- Key topics covered include strategic competitor assessment, market characterization, opportunities, barriers and challenges in the market along with SWOT analysis of the PD-1 and PD-L1 inhibitors market
- Pipeline analysis: Comprehensive data split across different phases and emerging trends and comparative analysis of marketed and pipeline molecules, pipeline molecules with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with latest updates
- Analysis of the current and future market competition in the global PD-1 and PD-L1 inhibitors drug market. Current scenario of market with upcoming blockbuster molecules and their impact on overall market.

Reasons to Buy

- The report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for PD-1 and PD-L1 inhibitors.
- Develop business strategies by understanding the trends shaping and driving for Immunotherapeutics market
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding PD-a and PD-L1 inhibitors pipeline in-depth
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners to enhance and expand business potential and scope
- Identifying the upcoming leaders in the PD-1 and PD-L1 inhibitors market in the coming years.

* The report is delivered in 2-3 business days.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Introduction

2. Executive Summary

3. Programmed Death 1 (PD-1)
- Programmed Death Ligand 1 (PD-L1)
- Role of PD-1 and PD-L1 pathways
- MOA of PD-1 and PD-L1 inhibitors
- Significance of PD-1 and PD-L1 inhibitors
- PD-1 and PD-L1 Active Therapy Areas & Epidemiology
- Metastatic Renal Cell Carcinoma
- Squamous Cell Carcinomas of the Head and Neck

4. Epidemiology
- Metastatic Colorectal Cancer
- Epidemiology
- Non-Small Cell lung cancer
- Epidemiology
- Biomarkers - PD-1 and PD-L1 inhibitors

5. Market Overview
- Comparative Analysis of Pipeline &Marketed Drugs
- Marketed Product of PD-1 and PD-L1 drugs - Overview
- Marketed Drug Candidate Profiles
- Marketed Drugs Sales

6. Details of Patent Expiry of Marketed Drugs
- Current and Future Market for PD and PD-L1 inhibitors:
- Challenges and Barriers associated with use of PD and PD-L1 inhibitors:
- PD-1/PD-L1Combinations Creating Boom
- Pipeline Therapeutics
- An overview of pipeline products
- Therapeutics under Development by MOA
- Therapeutics under Development by Companies
- Late Stage Products (Phase III)
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Pre-Clinical and Discovery Products
- Comparative Analysis
- Unknown Stages Molecules

7. Other Companies Inclination towards PD-1/PD-L1 Inhibitors
- Therapeutic Assessment of pipeline
- Therapeutics under Development by Product Type
- Therapeutics under Development by Phase for Monotherapy
- Therapeutics under Development by Phase for Combination therapy
- Therapeutics under Development by Molecule Type
- Therapeutics under Development by Route of Administration
- SWOT Analysis

8. Appendix
- Methodology
- Consulting Services
- Disclaimer

List of Tables

Table 1: Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2016
Table 2: PD-1 Marketed Drugs, 2016
Table 3: Sales of Marketed drugs, 2016
Table 4: Details of patent expiry of marketed molecules, 2016
Table 5:Bristol Myers Squibb’s drug-Opdivo (nivolumab) Partners for Combination Therapies
Table 6: Merck’s drug- Keytruda (Pembrolizumab) Partners for Combination Therapies
Table 7:AstraZeneca’s drug- Durvalumab (MEDI4736) Partners for Combination Therapies
Table 8: Roche’s drug-Atezolizumab (MPDL-3280A) Partners for Combination Therapies
Table 9: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2016
Table 10: ComparativeTable forPD-1 and PD-L1 inhibitors Drugs, 2016
Table 11: Number of Products under Development by Companies, 2016
Table12: Late Stage Products (Phase III and Filed), 2016
Table 13: Mid Stage Products (Phase II), 2016
Table 14: Early Stage Products (Phase I and IND), 2016
Table 15: Pre-Clinical and Discovery Products, 2016
Table 16: Number of Products by Product Type for PD-1 and PD-L1 Inhibitors, 2016
Table 17: Number of Monotherapy Products for PD-1 and PD-L1 inhibitors, 2016
Table 18: Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2016
Table 19: Number of Products under Development by Molecule Type, 2016
Table 20:Number of Products under Development by Route of Administration, 2016

List of Figures

Figure 1:Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2016
Figure 2: Sales of marketed drugs, 2016
Figure 3: Details of patent expiry of marketed molecules, 2016
Figure 4: Number of Products under Development forPD-1 and PD-L1 inhibitors Drugs, 2016
Figure 5: Comparative Graph forPD-1 and PD-L1 inhibitors Drugs, 2016
Figure 6:Late Stage Products (Phase III), 2016
Figure 7: Mid Stage Products (Phase II), 2016
Figure 8:Early Stage Products (Phase I and IND), 2016
Figure 9:Pre-Clinical and Discovery Products, 2016
Figure 10: Number of Products by Product Type forPD-1 and PD-L1 Inhibitors, 2016
Figure 11: Number of Monotherapy Products forPD-1 and PD-L1 inhibitors, 2016
Figure 12: Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2016
Figure 13: Percentage of pipeline drugs by Molecule Type (%), 2016
Figure 14:Percentage of pipeline drugs by Route of Administration(%), 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll